Back to Journals » ClinicoEconomics and Outcomes Research » Volume 13
Original Research
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cost-Utility Analysis of Dapagliflozin Compared to Sulfonylureas for Type 2 Diabetes as Second-Line Treatment in Indian Healthcare Payer’s Perspective
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
5,682 | Dovepress* | 4,674+ | 203 | 4,877 | |
PubMed Central* | 1,008 | 278 | 1,286 | ||
Totals | 5,682 | 481 | 6,163 | ||
*Since 22 October 2021 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
2 | 0 | 0 | 0 | 1 | 1 |
View citations on PubMed and Google Scholar